MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
Moderna EPS Ratio 2011-2026 | MRNA
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Moderna
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.26 | -9.28 | -12.3 | 21.3 | 30.3 | -1.96 | -1.55 | -4.95 | -4.18 | -3.79 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.3 | -12.3 | 0.627 |
Quarterly EPS Ratio Moderna
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.51 | -2.13 | -2.52 | - | 0.03 | -3.33 | -3.07 | - | -9.53 | -3.62 | 0.2 | - | 2.67 | 5.55 | 9.09 | - | 8.27 | 6.93 | 3.05 | - | -0.59 | -0.31 | -0.35 | -0.37 | -0.37 | -0.41 | -0.4 | -1.14 | -1.32 | -1.43 | -1.16 | -0.64 | -1.05 | -1.47 | -1.03 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.09 | -9.53 | -0.032 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.8 | 5.33 % | $ 9.14 B |  Australia |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-2.16 | $ 2.63 | -1.22 % | $ 16.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
42.2 | $ 88.34 | -3.22 % | $ 27.2 B | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-0.09 | $ 3.41 | -3.67 % | $ 230 B | Britain |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
2.39 | $ 316.2 | -4.28 % | $ 41.4 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-1.96 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
75.3 | $ 4.44 | -0.67 % | $ 730 M | Britain |
 |
Atreca
BCEL
|
-2.52 | - | -11.76 % | $ 5.79 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |
 |
argenx SE
ARGX
|
-7.99 | $ 743.15 | -0.68 % | $ 25 B |  Niderland |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
Aptorum Group Limited
APM
|
-0.78 | $ 0.89 | - | $ 4.85 M | China |
 |
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | USA |
 |
Cerus Corporation
CERS
|
-0.08 | $ 1.8 | -2.7 % | $ 343 M | USA |
 |
AbbVie
ABBV
|
1.02 | $ 202.28 | -2.11 % | $ 358 B | USA |
 |
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.04 | -1.28 % | $ 432 M | USA |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Coherus BioSciences
CHRS
|
1.43 | $ 1.63 | -2.69 % | $ 191 M | USA |
 |
AbCellera Biologics
ABCL
|
-0.49 | $ 3.32 | -2.06 % | $ 992 M | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
-2.4 | $ 8.12 | -1.22 % | $ 222 M |  Israel |
 |
Ardelyx
ARDX
|
-0.26 | $ 5.8 | -2.93 % | $ 1.4 B | USA |